Plexium

Transformative Precision Medicines for Patients in Need

San Diego, United States · Founded 2017 · $197.1M raised

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$197.1M
Last Round
$60.1M Venture RoundAug 2025
Rounds
4

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Plexium is a next-generation targeted protein degradation (TPD) biotech company developing monovalent degraders — including Monovalent Direct Degraders and Molecular Glues — using a proprietary ultra-high throughput cell-based screening (uHTS) platform. The company's AI-integrated drug discovery approach enables rational design of protein degrader therapeutics for cancer and neurodegenerative diseases. Plexium has established partnerships with Amgen and AbbVie for TPD drug discovery collaborations and maintains a wholly-owned pipeline alongside partnered programs.

Summary

Plexium is a Biotech company based in San Diego, United States, founded in 2017. It has raised $197.1M in total across 4 rounds, most recently a $60.1M Venture Round in Aug 2025. Investors include BVF Partners, TCGX and Lux Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundAug 2025
$60.1M

Sign up to see all 4 events

Funding: Seed through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Plexium on Indexed.vc
<a href="https://indexed.vc/companies/plexium"><img src="https://indexed.vc/api/badge/company/plexium" alt="Plexium on Indexed.vc" width="260" height="76" /></a>